Last reviewed · How we verify
AK112, Carboplatin, Paxlitaxel
AK112, Carboplatin, Paxlitaxel is a Bispecific antibody (PD-1/LAG-3 inhibitor) + chemotherapy combination Small molecule drug developed by Akeso. It is currently in Phase 3 development for Non-small cell lung cancer (in combination with carboplatin and paclitaxel), Other solid tumors (Phase 3 development).
AK112 is a bispecific antibody that simultaneously engages PD-1 on immune cells and LAG-3 on T cells to enhance anti-tumor immunity, combined with carboplatin and paclitaxel chemotherapy for direct tumor cell killing.
AK112 is a bispecific antibody that simultaneously engages PD-1 on immune cells and LAG-3 on T cells to enhance anti-tumor immunity, combined with carboplatin and paclitaxel chemotherapy for direct tumor cell killing. Used for Non-small cell lung cancer (in combination with carboplatin and paclitaxel), Other solid tumors (Phase 3 development).
At a glance
| Generic name | AK112, Carboplatin, Paxlitaxel |
|---|---|
| Sponsor | Akeso |
| Drug class | Bispecific antibody (PD-1/LAG-3 inhibitor) + chemotherapy combination |
| Target | PD-1 and LAG-3 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
AK112 functions as a dual checkpoint inhibitor by binding both PD-1 and LAG-3, removing inhibitory signals that suppress T cell activation and allowing enhanced anti-tumor immune responses. When combined with carboplatin (a platinum-based chemotherapy) and paclitaxel (a taxane that disrupts microtubule dynamics), the regimen provides both direct cytotoxic effects on cancer cells and immunological enhancement. This combination approach aims to improve response rates in solid tumors by leveraging both chemotherapy cytotoxicity and checkpoint-mediated immune activation.
Approved indications
- Non-small cell lung cancer (in combination with carboplatin and paclitaxel)
- Other solid tumors (Phase 3 development)
Common side effects
- Neutropenia
- Anemia
- Thrombocytopenia
- Nausea/vomiting
- Peripheral neuropathy
- Immune-related adverse events (irAEs)
Key clinical trials
- Prospective Multicenter Single-arm Trial: AK112 + Nab-paclitaxel/Carboplatin Neoadjuvant for TNBC (PHASE2)
- AK112 in Combination With Chemotherapy in Advanced Squamous Non-Small Cell Lung Cancer (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AK112, Carboplatin, Paxlitaxel CI brief — competitive landscape report
- AK112, Carboplatin, Paxlitaxel updates RSS · CI watch RSS
- Akeso portfolio CI
Frequently asked questions about AK112, Carboplatin, Paxlitaxel
What is AK112, Carboplatin, Paxlitaxel?
How does AK112, Carboplatin, Paxlitaxel work?
What is AK112, Carboplatin, Paxlitaxel used for?
Who makes AK112, Carboplatin, Paxlitaxel?
What drug class is AK112, Carboplatin, Paxlitaxel in?
What development phase is AK112, Carboplatin, Paxlitaxel in?
What are the side effects of AK112, Carboplatin, Paxlitaxel?
What does AK112, Carboplatin, Paxlitaxel target?
Related
- Drug class: All Bispecific antibody (PD-1/LAG-3 inhibitor) + chemotherapy combination drugs
- Target: All drugs targeting PD-1 and LAG-3
- Manufacturer: Akeso — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Non-small cell lung cancer (in combination with carboplatin and paclitaxel)
- Indication: Drugs for Other solid tumors (Phase 3 development)
- Compare: AK112, Carboplatin, Paxlitaxel vs similar drugs
- Pricing: AK112, Carboplatin, Paxlitaxel cost, discount & access